Cogent Biosciences Statistics
Share Statistics
Cogent Biosciences has 110.46M shares outstanding. The number of shares has increased by 27.08% in one year.
| Shares Outstanding | 110.46M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 14.47% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 88.93M |
| Failed to Deliver (FTD) Shares | 1.11K |
| FTD / Avg. Volume | 0.08% |
Short Selling Information
The latest short interest is 8.43M, so 7.63% of the outstanding shares have been sold short.
| Short Interest | 8.43M |
| Short % of Shares Out | 7.63% |
| Short % of Float | 9.48% |
| Short Ratio (days to cover) | 8.79 |
Valuation Ratios
The PE ratio is -2.43 and the forward PE ratio is -4.51.
| PE Ratio | -2.43 |
| Forward PE | -4.51 |
| PS Ratio | 0 |
| Forward PS | 599.6 |
| PB Ratio | 1.82 |
| P/FCF Ratio | -2.99 |
| PEG Ratio | n/a |
Enterprise Valuation
Cogent Biosciences Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 7.09, with a Debt / Equity ratio of 0.01.
| Current Ratio | 7.09 |
| Quick Ratio | 7.09 |
| Debt / Equity | 0.01 |
| Total Debt / Capitalization | 0.53 |
| Cash Flow / Debt | -110.84 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.75% and return on capital (ROIC) is -75.23%.
| Return on Equity (ROE) | -0.75% |
| Return on Assets (ROA) | -0.61% |
| Return on Capital (ROIC) | -75.23% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.17M |
| Employee Count | 164 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 68.44% in the last 52 weeks. The beta is 0.02, so Cogent Biosciences 's price volatility has been higher than the market average.
| Beta | 0.02 |
| 52-Week Price Change | 68.44% |
| 50-Day Moving Average | 10.44 |
| 200-Day Moving Average | 8.92 |
| Relative Strength Index (RSI) | 33.08 |
| Average Volume (20 Days) | 1.34M |
Income Statement
In the last 12 months, Cogent Biosciences had revenue of $0 and earned -$192.41M in profits. Earnings per share was $-2.42.
| Revenue | 0 |
| Gross Profit | -3.59M |
| Operating Income | -208.13M |
| Net Income | -192.41M |
| EBITDA | -205.86M |
| EBIT | - |
| Earnings Per Share (EPS) | -2.42 |
Balance Sheet
The company has $53.23M in cash and $18.85M in debt, giving a net cash position of $34.38M.
| Cash & Cash Equivalents | 53.23M |
| Total Debt | 18.85M |
| Net Cash | 34.38M |
| Retained Earnings | -603.62M |
| Total Assets | 384.02M |
| Working Capital | 288.48M |
Cash Flow
In the last 12 months, operating cash flow was -$153.62M and capital expenditures -$2.80M, giving a free cash flow of -$156.42M.
| Operating Cash Flow | -153.62M |
| Capital Expenditures | -2.80M |
| Free Cash Flow | -156.42M |
| FCF Per Share | -1.96 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
COGT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -29.44% |
| FCF Yield | -17.23% |
Analyst Forecast
The average price target for COGT is $15, which is 82.5% higher than the current price. The consensus rating is "Hold".
| Price Target | $15 |
| Price Target Difference | 82.5% |
| Analyst Consensus | Hold |
| Analyst Count | 6 |
Stock Splits
The last stock split was on Nov 9, 2020. It was a backward split with a ratio of 1:4.
| Last Split Date | Nov 9, 2020 |
| Split Type | backward |
| Split Ratio | 1:4 |
Scores
| Altman Z-Score | 3.76 |
| Piotroski F-Score | 2 |